Adebrelimab

Generic Name: Adebrelimab

Drug Type: Biotech

CAS Number: 2247114-85-6

Unique Ingredient Identifier: 1XBY50W1OX

Background: Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).

Indication: 用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。

Clinical Trials

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Interventions: Drug: Adebrelimab
Drug: Apatinib
Drug: Tegafur

First Posted Date: 2024-04-01

Last Posted Date: 2024-04-01

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 32

Registration Number: NCT06339619

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: HS-20089
Drug: Adebrelimab
Drug: Bevacizumab
Drug: Cisplatin / carboplatin

First Posted Date: 2024-03-29

Last Posted Date: 2024-07-18

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 1048

Registration Number: NCT06336707

Locations: 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Shanghai, Shanghai, China

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Phase 2

Not yet recruiting

Conditions: Non-squamous Non-small Cell Lung Cancer

Interventions: Drug: Camrelizumab + Pemetrexed + Carboplatin
Drug: Adebrelimab + Pemetrexed + Carboplatin
Drug: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin

First Posted Date: 2024-03-28

Last Posted Date: 2024-03-28

Lead Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd

Target Recruit Count: 401

Registration Number: NCT06335355

Locations: 🇨🇳
Affiliated Tumor Hospital of Shandong First Medical University, Jinan, Shandong, China

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: HS-20093
Drug: Adebrelimab
Drug: Cetuximab
Drug: Enzalutamide
Drug: Cisplatin/ Carboplatin

First Posted Date: 2024-03-27

Last Posted Date: 2024-07-18

Lead Sponsor: Hansoh BioMedical R&D Company

Target Recruit Count: 610

Registration Number: NCT06332170

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Adebrelimab + chemotherapy
Radiation: ±chest radiotherapy

First Posted Date: 2024-03-21

Last Posted Date: 2024-03-27

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 50

Registration Number: NCT06323265

Locations: 🇨🇳
Jun Wang, Shijiazhuang, Hebei, China

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Phase 2

Recruiting

Conditions: Biliary Tract Cancer
Gemox Chemotherapy

Interventions: Drug: Adebrelimab + GEMOX + TKI

First Posted Date: 2024-03-20

Last Posted Date: 2024-03-20

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 43

Registration Number: NCT06320301

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guanzhou, Guangdong, China

A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.

Phase 2

Not yet recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: adebrelimab
Drug: famitinib
Drug: chemotherapy

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-12

Lead Sponsor: Harbin Medical University

Target Recruit Count: 40

Registration Number: NCT06306560

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Phase 2

Not yet recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Adebrelimab
Drug: paclitaxel for injection (albumin bound)
Drug: Cisplatin or Carboplatin

First Posted Date: 2024-03-07

Last Posted Date: 2024-03-07

Lead Sponsor: Liaoning Tumor Hospital & Institute

Target Recruit Count: 36

Registration Number: NCT06299371

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Procedure: HAIC
Drug: Adebrelimab
Drug: Apatinib

First Posted Date: 2024-03-06

Last Posted Date: 2024-04-17

Lead Sponsor: Lei ZHAO

Target Recruit Count: 20

Registration Number: NCT06296563

Locations: 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Adebrelimab
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Bevacizumab

First Posted Date: 2024-02-28

Last Posted Date: 2025-02-17

Lead Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Target Recruit Count: 36

Registration Number: NCT06282445

Locations: 🇨🇳
The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy